Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 5;15(1):13.
doi: 10.1038/s41408-025-01219-7.

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy

Luciano J Costa  1 , Eva Medvedova  2 , Binod Dhakal  3 , Bhagirathbhai R Dholaria  4 , Kelly N Godby  5 , Susan Bal  5 , Gayathri Ravi  5 , Smith Giri  5 , Saurabh Chhabra  3   6 , Rebecca Silbermann  2 , Natalie S Callander  7
Affiliations

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy

Luciano J Costa et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Outcomes of patients with MRD-P.
Cumulative incidence of IMWG-defined PD among the patients with MRD-P (A). Survival free of failure of second-line therapy (SFF2T) of patients with MRD-P vs. those with PD not preceded by MRD-P (B). Overall survival of patients with MRD-P vs. those with PD not preceded by MRD-P (C).
See this image and copyright information in PMC

References

    1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. - PubMed
    1. Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003–14. - PubMed
    1. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2024;390:301–13. - PubMed
    1. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825–e837. - PubMed
    1. Rodríguez-Otero P, Moreau P, Dimopoulos MA, Beksac M, Perrot A, Broijl A, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. J Clin Oncol. 2024;42:7502.

LinkOut - more resources